Pharma firm Lupin Ltd today said it has received US health regulator's approval to sell generic version of oral contraceptive, Ortho Tri-cyclen Lo tablets in the American market.
The approval granted by the US Food and Drug Administration (USFDA) is for multiple strengths of norgestimate and ethinyl estradiol tablets in 0.18mg/0.025mg, 0.215 mg/0.025 mg and 0.25 mg/0.025mg, the company said in a filing to the BSE.
Norgestimate and ethinyl estradiol (Ortho Tri-cyclen Lo) tablets are indicated for prevention of pregnancy, it said.
Ortho Tri-cyclen Lo is patented by Janssen Pharmaceuticals Inc and it had sales of USD 421 million in the 12 months ended March 2012, the company said citing IMS Health sales data.
Shares of Lupin Ltd were trading at Rs 543.90 per share in the afternoon trade on BSE, up 0.09% from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app